Toxicity of intraocular daunomycin

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Daunomycin exhibits antiproliferative properties, suggesting potential therapeutic applications in proliferative vitreoretinopathy and post-cataract extraction capsular fibrosis.
• Prior animal studies indicated a narrow therapeutic window for daunomycin due to ocular structure damage at higher doses.

Purpose of the Study:

• To evaluate the safety and tolerability of daunomycin perfusion in human eyes, specifically in the context of vitreoretinal surgery.
• To establish reliable toxicity parameters for the human silicone-filled eye, as electrophysiology and histology are not readily applicable.

Main Methods:

• Clinical examination and fluorescein angiography were employed as primary toxicity assessment methods.
• Visual acuity and central visual field tests were used to evaluate retinal and macular function post-treatment.
• Daunomycin perfusion was administered at a concentration of 7.5 mg/l for 10 minutes.

Main Results:

• No specific daunomycin-related toxicity was observed in the patient cohort.
• Visual acuity was identified as a reliable indicator of retinal and macular function following vitreoretinal surgery.
• The daunomycin perfusion regimen was found to be well-tolerated by the human eye.

Conclusions:

• Daunomycin perfusion at the tested dosage is safe and well-tolerated in the human eye.
• Clinical parameters like visual acuity are effective for monitoring ocular function and toxicity after vitreoretinal procedures.
• Daunomycin holds promise for treating proliferative vitreoretinopathy and capsular fibrosis with a manageable safety profile.